Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.49
-0.6900-4.87%
Post-market: 13.650.1600+1.19%17:51 EDT
Volume:566.10K
Turnover:7.70M
Market Cap:745.24M
PE:-4.89
High:14.02
Open:13.88
Low:13.40
Close:14.18
52wk High:16.93
52wk Low:6.47
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.86
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.83
PE(LYR):-5.57

Loading ...

4dmt Completes Enrollment for 4front-2 Global Phase 3 Clinical Trial of 4d-150 in Wet Amd

THOMSON REUTERS
·
Jun 29

4dmt Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

THOMSON REUTERS
·
Jun 29

Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

Dow Jones
·
Jun 29

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of DR. Dean Baker

THOMSON REUTERS
·
Jun 26

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 117,720 in Common Shares

Reuters
·
Jun 26

4D Molecular Therapeutics CEO David Kirn disposes of 114,746 common shares worth $1.2 million

Reuters
·
Jun 24

4D Molecular Therapeutics Stockholders Back Directors and Governance

TIPRANKS
·
Jun 23

4D Molecular Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 23

4D Molecular Therapeutics grants 66,900 RSUs to seven new employees under inducement plan

Reuters
·
Jun 13

4D Molecular Therapeutics CEO David Kirn sells 1,922 shares worth $19,260.06

Reuters
·
Jun 03

4D Molecular Therapeutics to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

4D Molecular Therapeutics grants 141,100 RSUs to 14 new employees

Reuters
·
May 16

Daniel Giraldo Reiterates Buy on 4D Molecular Therapeutics, Citing Strong 4D-150 Progress and Undervalued Upside vs. $29 Price Target

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)

TIPRANKS
·
May 09

4D Molecular Therapeutics Inc - May Offer and Sell up to $400 Mln of Securities in Multiple Offerings - SEC Filing

THOMSON REUTERS
·
May 08

4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retinal gene therapy program

Reuters
·
May 08

4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate

Benzinga Earnings
·
May 08

BRIEF-4D Molecular Therapeutics Q1 Net Income USD -68.76 Million Vs. IBES Estimate USD -62.6 Million

Reuters
·
May 08

4D Molecular Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Reuters
·
May 05

4D Molecular Therapeutics to present at BofA Securities Healthcare Conference

Reuters
·
May 04